In 2021 the Strategic Advisory Group on Immunization to WHO recommended all countries to introduce at least two doses of IPV in their EPI schedule. At that time there were 99 countries with only one dose.

As of today, 55 countries have introduced the second dose, 34 Gavi supported and 21 middle income countries (MICs).

Supply capacity is sufficient for all countries to comply with the recommendation - offered quantities in response to the latest tender were three times the forecasted demand through UNICEF.

Tender completed and awards made for 2023 to 2025.

**Manufacturers have indicated that they can supply 100% of awarded quantities in 2023.**

- Demand reflects initial quantities approved for Gavi supported countries for 2023 plus requests to prepone 2024 allocations.

- Current expectations are that awards on LTAs for 2023 will be utilized at around 90%.

As manufacturers have scaled up production and improved efficiencies, they have been able to offer more affordable prices.

Affordability - the price of IPV is expected to decrease by 30% over the next 3 years to reach a weighted average price per dose of $1.69 by 2025.

COVID and other health priorities have resulted in limited resources for countries to roll out the second dose of IPV or apply to Gavi for support.

Vaccine security has been improved with at least two manufacturers awarded for each presentation.

Follow up and support the remaining 44 countries that only have one dose of IPV in their EPI schedule. These include 18 Gavi supported countries that have not applied to Gavi for support.

UNICEF will review the current LTA during first half of 2024 to determine whether to extend the LTA by 12 month or issue new tender.